Europe Menstrual Cramps Treatment Market, By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment Type (Medication, Therapy, Surgery, Others), Mode of Prescription (Over the Counter, Prescription), Route of Administration (Oral, Parenteral, Implants, Others), End User (Hospitals, Specialty Centers, Ambulatory Surgical Centers, Others), Distribution Channel (Pharmacies, Retail Sales, Direct Tender, Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2028
Market Analysis and Insights : Europe Menstrual Cramps Treatment Market
The menstrual cramps treatment is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.1% in the forecast period of 2021 to 2028 and is expected to reach USD 2,061.41 million by 2028 from USD 1,199.21 million in 2021. High demand of effective treatment for the menstrual health and rising technological advancement such as pain reliving devices and others are the major drivers which propelled the demand of the market in the forecast period.
Menstrual cramps treatment comprises features such as increasing need for effective treatment for menstrual cramps will impact in launching of new product by the manufactures into the market which enhance its demand as well as rising government and pharmaceutical industries initiatives leads to the market growth. Currently, awareness programmes are going on which is expected to create a competitive advantage for manufacturers to develop new and innovative technology. Moreover, these awareness programmes are also expected to provide various other opportunities in the menstrual cramp treatment market. However, presences of traditional therapies are expected to restraint the market growth in the forecast period.
Menstrual cramps are the cramping and throbbing pain in the lower abdomen of the body. Many women have menstrual cramps before and after the menstrual periods. For some women menstrual cramps are common while for other women menstrual cramps are annoying & quite sever which interfere in daily activities for a few days of every month. Symptoms of menstrual cramps are; pain that starts 1 to 3 days before the period, peaks 24 hours after the onset of the period and subsides in 2 to 3 days, dull, continuous ache, nausea, headache, dizziness, loose stools and others.
The menstrual cramps treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe Menstrual Cramps Treatment Market Scope and Market Size
The menstrual cramps treatment market is segmented on the basis of the type, treatment type, and mode of prescription, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the menstrual cramps treatment market is segmented into primary dysmenorrhea and secondary dysmenorrhea. In 2021, primary dysmenorrhea segment is dominating the menstrual cramps treatment market as majority of patients suffering from the primary or minor cramps symptoms.
- On the basis of treatment type, the menstrual cramps treatment market is segmented into medication, therapy, surgery and others. In 2021, medication segment is dominating the menstrual cramps treatment market due to medication nonsteroidal anti-inflammatory drugs and combined oral contraceptives represent first-line therapy for dysmenorrhea pain.
- On the basis of mode of prescription, the menstrual cramps treatment market is segmented into prescription and over the counter. In 2021, over the counter segment is dominating the menstrual cramps treatment market due to most of the drugs are available generic and supply of pharmaceutical products without any hindrance and raising awareness among the masses by the virtues of advertising.
- On the basis of route of administration, the menstrual cramps treatment market is segmented into oral, parenteral, implants and others. In 2021, oral segment is dominating the menstrual cramps treatment market due to oral segment is considered to be the first line of treatment. Furthermore, the growing demand for various oral drug administration serves as another driving factor
- On the basis of end user, the menstrual cramps treatment market is segmented into hospitals, ambulatory surgical centers, specialty centers and others. In 2021, hospitals segment is dominating the menstrual cramps treatment market because most patients are experiencing menopausal symptoms so they would be seen in the hospital to get proper diagnosis and treatment.
- On the basis of distribution channel, the menstrual cramps treatment market is segmented into direct tender, retail sales, pharmacies and others. In 2021, pharmacies segment is dominating the menstrual cramps treatment market as variety of drugs is used in hospital pharmacies to treat menopausal disorders.
Menstrual Cramps Treatment Market Country Level Analysis
The menstrual cramps treatment market is analysed and market size information is provided by the country, type, treatment type, mode of prescription, route of administration, end user and distribution channel as referenced above. The countries covered in the Europe menstrual cramps treatment market report are the U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Turkey, Belgium, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe.
Mode of prescription segment in Europe is expected to dominate the market due to the high adoption of OTC menstrual cramps treatment by the patients in the region. Germany is dominating in the market and leading the growth in the European market due to increased consumption of OTC drugs in the region. France hold a second highest market share due to increased healthcare investment. while, U.K. is growing with the fastest CAGR because of increased number of female population with menstrual disease.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by Manufactures are Creating New Opportunities for Players in the Menstrual cramps Treatment Market
Menstrual cramps treatment market also provides you with detailed market analysis for every country growth in aesthetic industry with menstrual cramps treatment sales, impact of advancement in the menstrual cramps treatment and changes in regulatory scenarios with their support for the menstrual cramps treatment market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Menstrual Cramps Treatment Market Share Analysis
Menstrual Cramps Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to menstrual cramps treatment
The major companies which are dealing in the menstrual cramps treatment are Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Color Seven Co., Ltd., Beurer GmbH, Mylan N. V. (a part of Viatris Inc.), Boehringer Ingelheim International GmbH, PMS4PMS, LLC, Sanofi, Nobelpharma Co., Ltd., ObsEva, Myovant Sciences Ltd., AbbVie Inc., BioElectronics Corporation, LIVIA, Alvogen, Cumberland Pharmaceuticals Inc., Lupin Pharmaceuticals, Inc. (a subsidiary of LUPIN), Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc. ), Sun Pharmaceutical Industries Ltd. among others domestic and Europe players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the menstrual cramps treatment market.
For instance,
- In April 2013, Pfizer Inc., announces the launch of ADVIL and ADVIL RELIEF in Action campaign. This launched has helped to strengthen its footprints in the market. As well as provided tremendous opportunity for business expansion.
- In Sept 2020, Cumberland Pharmaceuticals Inc. announced the launch of Caldolor (ibuprofen) Injection in a ready-to-use bag. The launch of the new product administered without dilution for pain relief. It is estimated that, this product launch has anticipated escalating product portfolio and revenue growth of the company.
Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the menstrual cramps treatment market which also provides the benefit for organization to improve their offering for menstrual cramps treatment.
SKU-